Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients With Chronic Migraine

Trial Profile

A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients With Chronic Migraine

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eptinezumab (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Alder Biopharmaceuticals

Most Recent Events

  • 06 Jun 2021 Results of pooled analysis from 4 studies: (NCT01772524, NCT02275117, NCT02559895 (PROMISE-1), and NCT02974153 (PROMISE-2)) assessing the cardiovascular safety profile, CV risk in patients with migraine and mild to moderate CV risk factors, with few CV-related TEAEs and in few patients starting new or changing their dose of CV medication, presented at the 63rd Annual Scientific Meeting of the American Headache Society.
  • 24 Jun 2019 Results published in the Cephalalgia
  • 10 Sep 2017 Results of this trial and 2 other trials (refer CTP: 228412, 259778) were presented at the 2017 International Headache Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top